Cara Therapeutics Inc. (CARA): יחס חוב להיוון בספרים

The balance sheet financial leverage of Cara Therapeutics, Inc. (CARA) helps assess the stability of the company, which develops pruritus treatments for patients with kidney failure. While integrating medications into nephrological care improves patient quality of life, the suspension of trials has led to a reduction in operations. The value of 0.02 serves as a baseline indicator of the current debt load, allowing for the tracking of the share of borrowed funds through the prism of the market value of assets.

This indicator measures the business's reliance on borrowed funds relative to its equity. A rising ratio signals declining financial stability and an increase in bankruptcy risks. By analyzing the ratio of total liabilities to book capitalization, an investor assesses the company's margin of safety. This is critical for Cara Therapeutics, Inc. (CARA), as the stagnation of clinical programs weakens operational momentum. Current royalties only temporarily mask the need for new funding sources.